James LynchDaily Caller ReporterA report by multiple House Committees found the U.S. Food and Drug Administration inappropriately colluded with drug company Biogen before approving its Alzheimer’s drug Aduhelm.The report was released after an 18-month investigation by the House Oversight and Energy and Commerce Committees into the FDA’s decision to approve Aduhelm.FDA officials and Biogen had at least 115 calls, 40 meetings and many email exchanges over the course of a year starting in July 2019, according to the committee report. These interactions were “atypical” and failed to follow the FDA’s documentation protocols, the report says.The FDA and Biogen inappropriately collaborated on a briefing document for the PCNS Advisory Committee that did not reflect di
